Monday, December 25, 2017

Straight from the Heart: IMA ICMR Initiatives - Annual Round Up



IMA endorses National Guidelines for Stem Cell Research (NGSCR): The NGSCR-2013 covers only stem cell research, both basic and translational, and not therapy as the same is experimental as on date. Any stem cell use in patients, other than that for hematopoietic stem cell reconstitution for approved indications, is investigational and must only be done within the purview of an approved and monitored clinical trial. Every use of stem cells in patients outside an approved clinical trial is malpractice.

Points about stem cell therapy every IMA member must know

·         There are no approved indications for stem cell therapy other than the hematopoietic stem cell transplantation (HSCT) for haematological disorders. Stem cell therapies other than HSCT are investigational and can be conducted only in the form of a clinical trial following ICMR guidelines for clinical research after obtaining necessary regulatory approvals. Use of stem cells for any other purpose outside the domain of clinical trial is unethical (Clause 10.3.1)

·         Any violation of ICMR Clinical Research Guideline are actionable professional misconduct under “Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations 7.22 “Research: Clinical drug trials or other research involving patients or volunteers as per the guidelines of ICMR can be undertaken, provided ethical considerations are borne in mind. Violation of existing ICMR guidelines in this regard shall constitute misconduct. Consent taken from the patient for trial of drug or therapy which is not as per the guidelines shall also be construed as misconduct.”

·         One dealing with pharmaceuticals and or allied industry one also need to follow 6.8.1 e regulation of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations:” Medical Research: A medical practitioner may carry out, participate in, work in research projects funded by pharmaceutical and allied healthcare industries. A medical practitioner is obliged to know that the fulfilment of the following items (i) to (vii) will be an imperative for undertaking any research assignment / project funded by industry – for being proper and ethical. Thus, in accepting such a position a medical practitioner shall:- (i) Ensure that the particular research proposal(s) has the due permission from the competent concerned authorities. (ii) Ensure that such a research project(s) has the clearance of national/ state / institutional ethics committees / bodies. (iii) Ensure that it fulfils all the legal requirements prescribed for medical research. (iv) Ensure that the source and amount of funding is publicly disclosed at the beginning itself. (v) Ensure that proper care and facilities are provided to human volunteers, if they are necessary for the research project(s). (vi) Ensure that undue animal experimentations are not done and when these are necessary they are done in a scientific and a humane way. (vii) Ensure that while accepting such an assignment a medical practitioner shall have the freedom to publish the results of the research in the greater interest of the society by inserting such a clause in the MoU or any other document / agreement for any such assignment”

The MCI ethics violation will attract “First time censure, and thereafter removal of name from Indian Medical Register or State Medical Register for a period depending upon the violation of the clause.”

·         Stem cells clinical trials for conditions other HSCT will require approval from Institutional Ethics Committee (IEC) and Institutional Committee for Stem Cell Research (IC-SCR) and CDSCO. The IEC should be registered with Central Drug Standards Control Organization DSSCO and IC-SCR with National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT). Only registered entities are permitted to conduct these trails. Stem cells used for intervention should be processed/developed under CDSCO certified GMP facility.

·         Clinical trials using human stem cells should be in compliance with Schedule Y of Drugs and Cosmetics Act and GCP Guidelines of CDSCO (www.cdsco.nic.in) as well as ICMR-Ethical Guidelines for Biomedical Research involving Human Participants (http://www.icmr.nic.in/ethical_guidelines.pdf). All clinical trials on stem cells shall be registered with Clinical Trial Registry India (CTRI). (Clause 10.2)

o    Any violation will be a professional misconduct as per MCI ethics regulation 1.9  to be read with regulation 7.1

o    1.9: “Evasion of Legal Restrictions: The physician shall observe the laws of the country in regulating the practice of medicine and shall also not assist others to evade such laws. He should be cooperative in observance and enforcement of sanitary laws and regulations in the interest of public health. A physician should observe the provisions of the State Acts like Drugs and Cosmetics Act, 1940; Pharmacy Act, 1948; Narcotic Drugs and Psychotropic substances Act, 1985; Medical Termination of Pregnancy Act, 1971; Transplantation of Human Organ Act, 1994; Mental Health Act, 1987; Environmental Protection Act, 1986; Pre–natal Sex Determination Test Act, 1994; Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954; Persons with Disabilities (Equal Opportunities and Full Participation) Act, 1995 and Bio-Medical Waste (Management and Handling) Rules, 1998 and such other Acts, Rules, Regulations made by the Central/State Governments or local Administrative Bodies or any other relevant Act relating to the protection and promotion of public health”.

o    MISCONDUCT: The following acts of commission or omission on the part of a physician shall constitute professional misconduct rendering him/her liable for disciplinary action
o    7.1   Violation of the Regulations: If he/she commits any violation of these Regulations. 

·         The physician/scientist engaged in stem cell research shall avoid any activity that leads to unnecessary hype, or unrealistic expectations in theminds of study participants or public at large regarding stem cell therapy. The study participant and other responsible family members must be given adequate and unbiased information about the trial protocol, its limitations and potential adverse effects. (Clause 7.5). The same is also actionable under The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

o    Promotional advertisements by private banks offering storage of cord blood for possible- future use are misleading. As there is no scientific basis for preservation of cord blood for future self-use at present, this practice is not recommended. The only exception is when there is a child with a haematological disease curable by HPSC and the mother is pregnant. In such situation storage and release of stem cells from cord blood of the new-born sibling,  subject to HLA match shall be recommended. On the other hand, parents should be encouraged for voluntary donation to public cord blood banks for allogeneic transplantation and research purposes. (Clause 12.2)

o    "Disclaimers / Qualifiers" the advertisements should carry so that there is a standard declaration which is unambiguous to a lay consumer?

·         The IC-SCR and IEC shall ensure that the patients/participants recruited under clinical trial shall not be charged including hospital stay and laboratory based investigations. (Clause 10.2.5.5)

·         Prior to enrolment of subjects in clinical trials or procurement of stem cells for research, it is mandatory to obtain informed consent from thedonor. (Clause 4.1)

·         Independent informed consent in advance should be obtained for termination pregnancy and for donation of the foetal material for research.  There should be no inducement for donation of gametes/embryos/somatic cells by way of payment or in of lieu of medical services, except for reimbursement of reasonable expenses for travel and loss of wages incurred by the person (amount to be decided by IC-SCR/ IEC). (Clause 13.1.2)

·         Use of Umbilical cord blood stem cells (except when the HPSCs are used for conditions approved for bone marrow HPSC transplantation) , HSC or MSC is experimental at present and shall be permitted only under conditions of controlled clinical trial by the IC-SCR/IEC (Clause 12.2)

o    In most of the haematological/genetic disorders, child’s own stored cord blood stem cells cannot be used for the same child as those will carry the same defect. 

·         An institution or laboratory developing or processing stem cells for human use should obtain NABL accreditation for all laboratory procedures required for product development.

Presidential address on 28th December I spoke “IMA also wants the government to declare a special fund for rare diseases and orphan drugs.”

ICMR set up a registry of rare diseases. Apart from maintaining a database, the registry, set up on April 28 2017, will also help formulate policies on funding, treatment and more. A disease is defined as rare when it affects less than one in 2,500 individuals. Over 70mn Indians suffer from such disorders and live with them throughout their lives.   There are only 500 FDA-approved drugs for over 7,000 rare diseases globally.  There is often no cure, only supportive care. Treatment is extremely costly too, ranging from lakhs to crores a year.  The health ministry is currently discussing a draft policy for treatment of rare diseases.

In Gorakhpur issue IMA raised the absence of autopsies in such cases

The under-five mortality rate in India stands at 50 per 1000 live births. The pilot project that will begin in January, 2018, at New Delhi’s Safdarjung hospital, is a part of the global CHAMPS— Child Health and Mortality Prevention Surveillance, project, wherein tissue biopsies of the brain, liver, spleen and other tissues are taken in a minimally invasive way. This will benefit in districts like Gorakhpur where child deaths are high. For six months— January to June, all child deaths that take place at Safdarjung hospital will be examined. Informed consent will be taken from the parents.

IMA Women Life Time Achievement Award to ICMR DG

Other issues: C. auris ICMR advisory, AMR, NCD

May Measurement Month


Sunday, December 24, 2017

Straight from the Heart: Status of legal cases


Dr KK Aggarwal
National President
Dear All
The following is the status of the pending cases of IMA as on 19.12.2017.
Mr Rahul Gupta
Advocate


Sr. No.
                                    Case Details
Next Date of Hearing
1.      
The matter titled as "Sultan Singh Dhobi versus UOI & Others" pending before Hon'ble Central Administrative Tribunal, Delhi was listed for hearing on 13.11.2017. Ms. Aanchal Dhingra, Advocate appeared on behalf of IMA Hq and had filed the reply on behalf of IMA. The matter is listed for final hearing.

22.12.2017
2.      
The matter titled as "IMA versus Arth Business Centre CS(Comm.) No. 122/2017” has been filed by IMA Hq. against Arth Business Centre for recovery of arrears of rent and damages was filed and was listed for hearing before Hon'ble High Court of Delhi on 12.07.2017 Mr. Rahul Gupta, Mr. Shekhar Gupta and Ms. Ira Gupta, Advocates have appeared on behalf of IMA. Notice to the defendant namely Arth Business Centre has been issued by the Hon'ble High Court of Delhi but Arth Business is deliberately avoiding the service of summons. On 06.09.2017 and 28.11.2017, Mr. Shekhar Gupta and Ms. Ira Gupta, advocates had appeared and had requested the court to serve the defendant by way of email also. The service has been done through email and other modes.

03.01.2018
3.      
The matter titled as Baharul Islam & Others versus IMA Assam Branch & Others, SLP No. 32592 - 32593/2015" pending before Hon'ble Supreme Court was listed for hearing on 11.09.2017. An impleadment application on behalf of IMA Hq. has been filed in the said case. Mr. Rahul Gupta and Mr. Shekhar Gupta, advocate had appeared on behalf of IMA. The said case is listed for final hearing on the issue relating to crosspathy.

04.01.2018
4.      
The matters titled as "All India Indian Medicine Graduates Association versus Delhi Medical Association & Others, SLP (Civil) No. 20144-20145/2016” and "National Integrated Medical Association versus Delhi Medical Association & Others, SLP (C) No. 14297/2016" were listed for hearing. Mr. Rahul Gupta, Advocate had appeared on behalf of Delhi Medical Association and had accepted notice of the said cases.

15.01.2018
5.      
The violence against doctors matter titled as "Court on its Own Motion versus UOI &Other, WP(C) 3903/2017” was listed before the Delhi High Court on 20.11.2017. In the said case, the Hon'ble Chief Justice of Delhi High Court has suo moto made the Indian Medical Association as a party. Mr. Rahul Gupta Advocated had appeared on behalf of IMA. An affidavit has been filed on behalf of IMA. The Hon'ble Court has adjourned the matter after giving some time to Mr. Sanjay Jain and Mr. Siddharth Aggarwal, Senior Advocates to understand the reasons behind violence against doctors and also to find solutions for stopping the same.

18.01.2018
6.      
The matter titled as "State of Andhra Pradesh versus Ganjikuntla Sridhar & Others, SLP(Civil) 10347-10359/2017" was listed for hearing on 27.07.2017 in which the Hon'ble Supreme Court has suo moto appointed IMA as amicus curiae. The Hon’ble Supreme Court has asked for IMA’s view on the issue of the case.

19.01.2018
7.      
The matters titled as "Indian Radiological and Imaging Association versus UOI & Anr., SLP (C) 11046/2016" and "Union of  India versus Indian Radiological & Imaging Association & Others, SLP (C) No. 16657/2016" were listed for hearing on 05.10.2017. An impleadment application on behalf of IMA Hq. has to be filed in the said case. Mr. Rahul Gupta, Mr. Gagan Gupta, Mr Shekhar Gupta and Ms. Ira Gupta, Advocates appeared on behalf of IMA Hq. The UOI has filed an application for the stay of high court judgment. However, on 07.11.2016 the Hon'ble Supreme Court has not passed any orders of stay and the UOI has been directed to file an application for transfer of similar cases pending before various High Courts in the country. The matter is relating to the issue of PCPNDT. The next date of hearing is 13.12.2017.

19.01.2018
8.      
The pollution matter titled as "Indian Medical Association versus UOI & Others W.P.(Civil) 895/2016 was listed for hearing on 11.11.2016. Mr. Gopal Subhramanian, Senior Advocate, Mr. Rahul Gupta, Mr. Shekhar Gupta, Mr. Gagan Gupta and Ms. Ira Gupta, Advocates appeared on behalf of IMA. Thereafter, the matter was listed for completion of pleadings on which date Mr. Gagan Gupta, Advocate appeared on behalf of IMA.

25.01.2018
9.      
The matter titled as "MCI versus Dr. Meenakshi Gautam, Cont. App. 17/2015” pending before Delhi High Court was listed for hearing on 21.09.2017. Ms. Ira Gupta, Advocate appeared in the said case on behalf of IMA. In the said case, an impleadment application has been filed on behalf of IMA and notice has been issued on the said impleadment application by the Hon'ble Court. On 21.09.2017 the matter was simply adjourned as the MCI has filed an application for clarification of order passed in the Writ Petition.

12.02.2018
10.   
The Surrogacy Writ Petition titled as "Jayashree Wad versus UOI & Others W.P.(Civil) 95/2015” pending before the Hon'ble Supreme Court was listed for hearing on 07.03.2017. Mr. Rahul Gupta, Advocate appeared in the said case on behalf of IMA. In the said case, an impleadment application has been filed on behalf of IMA. The Hon'ble Supreme Court of India has held that all the matters relating to surrogacy will be heard once the Assisted Reproductive Technology (Regulation) Bill, 2014 is enacted as an act of Parliament with or without modification, as may be. The mater has been admitted on 11.07.2017.

Admitted

Saturday, December 23, 2017

Never forget we are different



Dr KK Aggarwal
National President

We are doctors, we are demi Gods, we are next to God, and so we cannot be inhuman. We not only need to be scientifically and legally correct but also morally and ethically correct. As doctors, we are supposed to follow two bioethics principles: non-maleficence (first do no harm) and beneficence (welfare of all).

Compassion is inherent to our profession as are compassionate doctors. Compassion should be demonstrated in practice as much as felt. A compassionate attitude in practice is more important than the science. Poor, inconsiderate and uncompassionate communication is the reason why most patients sue.

The etymology of "compassion" is Latin, meaning "co-suffering." Compassion involves "feeling for another" and is a precursor to empathy, the "feeling as another".

Compassion is considered in almost all the major religious traditions as among the greatest of virtues.

But, it is not the same as empathy or altruism. While empathy refers more generally to our ability to appreciate the perspective of and feel the emotions of another person, compassion is when those feelings and thoughts include the desire to help.

Altruism is the kind, selfless behavior often prompted by feelings of compassion, though one can feel compassion without acting on it, and altruism isn’t always motivated by compassion.


Today, everybody wants to regulate us. If we are demi Gods we do not need a regulator. God regulates others. We the medical professionals need to wake up and adopt and abide by the IMA self-regulation policies and also regulate policies for the corporate.

Friday, December 22, 2017

Straight from the Heart: Medical Uptodate Year Roundup 2017


·         Elvitegravir-cobicistat use during pregnancy: For HIV-infected women who become pregnant while on an elvitegravir-cobicistat-containing regimen switch to a different regimen (1,2).
·         Acetylcysteine IV or oral does not prevent contrast nephropathy (3).
·         Frequency for dosing of oral iron for individuals with iron deficiency should be every other day rather than every day (4).
·         Patients ≥60 years of age with new onset dyspepsia should undergo an upper endoscopy (5).
·         Patients <60 years with new onset dyspepsia upper GI endoscopy is reserved for those with clinically significant weight loss, overt gastrointestinal bleeding, more than one alarm feature, or rapidly progressive alarm features. These patients should be tested and treated for H. pylori infection (5).
·         For patients with suspected multiple myeloma do cross-sectional imaging (low-dose CT, PET/CT, or MRI scan), rather than a skeletal survey, as the imaging modality to detect bone involvement (6).
·         For patients age ≤60 years with an embolic-appearing cryptogenic ischemic stroke who have a patent foramen ovale with a right-to-left shunt detected by saline contrast bubble study go for percutaneous PFO closure in addition to antiplatelet therapy, rather than antiplatelet therapy alone (8,9).
·         For patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) and a left-sided primary tumor, treat with an antibody targeting the epidermal growth factor receptor (EGFR), rather than bevacizumab, when a biologic agent is chosen as a component of first-line therapy (10).
·         For most patients with RAS/BRAF wt mCRC and a right-sided primary tumor treat with bevacizumab rather than an anti-EGFR antibody in conjunction with first-line chemotherapy (10).
·         In mild to moderate treatment resistant major depression augment the initial antidepressant with a second drug and/or psychotherapy, rather than other strategies such as switching antidepressants or switching from pharmacotherapy to psychotherapy (11).
·         For patients with chronic HCV genotype 1 infection who have not been previously treated with sofosbuvir or an NS5A inhibitor give ledipasvir-sofosbuvir, sofosbuvir-velpatasvir, or glecaprevir-pibrentasvir (12-16).
·         For patients with advanced systemic mastocytosis give midostaurin for initial systemic therapy rather than imatinib or other cytoreductive therapies (17, 18).
·         In patients with a presumptive diagnosis of acquired TTP administer rituximab as a component of initial therapy (19).
·         For patients with cutaneous melanoma and a positive sentinel lymph node biopsy go for clinical observation and ultrasound surveillance of the positive nodal basin rather than immediate completion lymph node dissection [20].
·         For patients with newly diagnosed ALK-positive NSCLC go for alectinib as first-line treatment.  For those without access to alectinib, appropriate alternatives include crizotinib or ceritinib. For patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), crizotinib has been administered as frontline therapy. However, newer agents have shown promising efficacy in advanced ALK-positive NSCLC (22,23).
·         For patients with an asymptomatic solid or subsolid (pure ground glass or part-solid) solitary pulmonary nodule (SPN) <6 mm, no routine follow-up is required. For patients with solid SPNs that have been stable on serial CT over a two-year period, or with subsolid SPNs that have been stable over a five-year period, we suggest no further diagnostic testing (24).
·         For women with postpartum hemorrhage diagnosed within three hours of delivery administer tranexamic acid as a component of overall treatment (25).
·         For patients with ALS who have a disease duration of two years or less, are living independently, and have an FVC ≥80 percent treat with edaravone and edaravone for patients with more advanced ALS (26,27).
·         For adults with acquired severe aplastic anemia who are not candidates for allogeneic hematopoietic cell transplantation treat with eltrombopag plus standard immunosuppressive therapy (IST) rather than IST alone (28).
·         For patients with primary progressive multiple sclerosis treat with ocrelizumab (29).
·         Scalp hypothermia can prevent chemotherapy-induced alopecia in women with breast cancer (30,31).
·         Do not give venom immunotherapy (VIT) to patients with reactions to stinging insects limited to cutaneous systemic symptoms and not involving other organ systems. However, VIT is effective in reducing the severity of future reactions and may still be offered in selected situations (32).
·         For most patients with chronic HBV infection who initiate therapy with tenofovir give tenofovir alafenamide rather than tenofovir disoproxil fumarate (tenofovir DF). Those initially started on tenofovir DF switch to tenofovir alafenamide (33-35).

References

1.     http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/ (Accessed on October 19, 2017).
2.     7th International Workshop on HIV and Women. Seattle, WA. February 11-12, 2017.
3.     N Engl J Med 2017.
4.     Lancet Haematol 2017; 4:e524.
5.     Am J Gastroenterol 2017; 112:988.
6.     Blood Cancer J 2017; 7:e599.
7.     N Engl J Med 2017; 377:1022.
8.     N Engl J Med 2017; 377:1033.
9.     N Engl J Med 2017; 377:1011.
10.  Eur J Cancer 2017; 70:87.
11.  JAMA 2017; 318:132.
12.  52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.
13.  Lancet Infect Dis 2017; 17:1062.
14.  American Association for the Study of Liver Diseases Liver Meeting, Boston, MA, November 11-15, 2016.
15.  N Engl J Med 2017; 377:1448.
16.  N Engl J Med 2017; 376:2134.
17.  Leukemia 2017.
18.  N Engl J Med 2016; 374:2605.
19.  Blood Advances 2017; 1:1159.
20.  N Engl J Med 2017; 376:2211.
21.  N Engl J Med 2017; 377:829.
22.  Lancet 2017; 390:29.
23.  WCLC 2016; PL03.07.
24.  Radiology 2017; 284:228.
25.  Lancet 2017.
26.  Lancet Neurol 2017; 16:505.
28.  N Engl J Med 2017; 376:1540.
29.  N Engl J Med 2017; 376:209.
30.  JAMA 2017; 317:596.
31.  JAMA 2017; 317:606.
32.  Ann Allergy Asthma Immunol 2017; 118:28.
34.  Lancet Gastroenterol Hepatol 2016; 1:185.
35.  Lancet Gastroenterol Hepatol 2016; 1:196.

(Source: Uptodate)